Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia

Tissue Engineering Conjunctiva Transplantation and Conjunctival Sac Formation for the Treatment of Pterygium and Atretoblepharia

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02911532

Acronym

TECTPA

Enrollment

Registered

2016-09-22

Start date

2016-10-01

Completion date

2018-04-01

Last updated

2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pterygium

Keywords

pterygium, tissue engineering, atretoblepharia

Brief summary

The purpose of this study is to determine whether tissue engineering conjunctiva is effective in the treatment of pterygium and atretoblepharia.

Detailed description

The most important area for research on the pterygium are the recurrence occurred after operation. Now the best way to prevent the recurrence is autologous conjunctival stem cell transplantation, but this way of operation can cause lack of conjunctiva and conjunctival scar, even may effect the later glaucoma surgery. For the atretoblepharia patients, amniotic membrane transplantation and autologous oral mucosa transplantation can not make effect to alleviate it. In this pilot project, investigators would like to study the effect of tissue engineering conjunctiva transplantation in the treatment of pterygium and tissue engineering conjunctiva transplantation combined with conjunctiva sac formation for the treatment of atretoblepharia. This will allow us to determine if useful data can be obtained, and if so, lead to further studies in various conjunctiva loss caused by trauma, infections, and so on.

Interventions

PROCEDURETissue engineering conjunctiva transplantation

During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Primary and recurrent pterygium patients,atretoblepharia patients 2. Voluntarily signed informed consent 3. No surgery and anesthesia contraindications.

Exclusion criteria

1. The patients combined systemic diseases 2. Reject study and follow visit 3. Patients don't accept the tissue engineering conjunctiva 4. Cannot tolerate surgery or anesthesia

Design outcomes

Primary

Measure	Time frame
The epithelial defect size of the transplanted tissue engineering conjunctiva	the 7 days after operation

Countries

China

Contacts

Primary ContactSuxia Li, researcher

ykyykjk@163.com8615854107085

Backup ContactHua Gao, researcher

gaohua100@126.com8613705312702

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026